Show simple item record

dc.contributor.authorRuiz, Begueire J.
dc.contributor.authorFernández, Julia
dc.contributor.authorStringa, Matias.
dc.contributor.authorAnaya, Javier.
dc.date.accessioned2020-02-14T18:15:59Z
dc.date.available2020-02-14T18:15:59Z
dc.date.issued2017-10-25
dc.identifier.citationInt J Dermatol. 2017 Mar;56(3):324-326.en_US
dc.identifier.issn0011-9059
dc.identifier.urihttps://riu.austral.edu.ar/handle/123456789/798
dc.description.abstractLangerhans cell histiocytosis (LCH) is a disease characterized by clonal proliferation and a pathological infiltration of Langerhans cells in one or more organs, in which almost every tissue may be involved. Its incidence is slightly increased in males.1,2 It is more common in children (only 2% of LCH patients are aged over 70 years), and it may involve multiple systems or may be localized.1 Although it is not a malignancy, LCH may cause the selfdestruction of involved tissues, such as bone, skin, lung, and brain tissue.2,3 Langerhans cell histiocytosis with isolated involvement of the skin or mucous membranes is rare and occurs in only 4–7% of cases.1,2 The occurrence of LCH that is restricted to the vulva is very rare, and fewer than 26 such cases have been published in the literature. We describe a very interesting case in a patient who demonstrated an excellent response to thalidomide.en_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.subjectVulvar Diseases/drug therapyen_US
dc.subjectVulvar Diseases/etiologyen_US
dc.subjectHistiocytosis, Langerhans-Cell/complicationsen_US
dc.titleVulvar Langerhans cell histiocytosis and thalidomide: an effective treatment optionen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record